SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Table 2 Associations between the SULT1A1 rs9282861 genotypes, adjuvant treatment and overall survival (OS)

Cases	n	HR	95% CI	P ^§	median OS (years)
chemotherapy only	76				13.0
GG or AG	62	1^†			11.0
AA	14	0.33	0.10 to 1.09	0.068	16.0
TAM only	65				9.2
GG or AG	47	1^‡			8.2
AA	18	0.53	0.27 to 1.08	0.079	11.9
chemotherapy/TAM^¥	145				10.0
GG or AG	112	1^†			9.1
AA	33	0.50	0.29 to 0.88	0.015	13.7

Abbreviations: TAM = tamoxifen
^§ P was based on Cox proportional analysis
^†Reference value; HRs adjusted for age and stage at diagnosis, radiation therapy, and hormone receptor status
^‡Reference value; HRs adjusted for age and stage at diagnosis, and radiation therapy
^¥Four patients received chemotherapy and TAM

ISSN: 1471-2407